Briacell Therapeutics (QB) Stock Price

0.24 (6.22%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Briacell Therapeutics Corporation (QB) BCTXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.24 6.22% 4.10 16:13:35
Open Price Low Price High Price Close Price Previous Close
4.09 4.09 4.11 4.10 3.86
Bid Price Ask Price Spread News
3.66 4.12 0.46 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6 1,070 $ 4.1008 $ 4,388 315 0.022455 - 20.36
Last Trade Time Type Quantity Stock Price Currency
15:51:19 500 $ 4.10 USD

Briacell Therapeutics (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.17M 771.96k 480.28k $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
316.00 $ - 0.00% - -

more financials information »

Briacell Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BCTXF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.77054.113.69063.726660.32958.74%
1 Month4.104.253.69063.991,2670.000.0%
3 Months4.644.843.254.11760-0.54-11.64%
6 Months6.757.313.255.05895-2.65-39.26%
1 Year0.032820.360.0224550.233087230,4014.0712,400.0%
3 Years0.101320.360.0224550.118699130,9094.003,947.38%
5 Years0.166920.360.0224550.124243327,2953.932,356.56%

Briacell Therapeutics (QB) Description

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs INCMGA00012 and epacadostat (listed in ClinicalTrials.gov as NCT03328026). BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Additionally, BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

Your Recent History
Briacell T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.